Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats

NeuroReport

Volumn 21, Issue 12, 2010, Pages 837-840

  Yang, Xinxin ^a   Yuan, Weien ^b   Ren, Tianan ^b   Song, Lu ^a   Wu, Na ^a   Liu, Zhenguo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

levodopa induced dyskinesia; levodopa benserazide loaded biodegradable microspheres; Parkinson's disease

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG RELEASE; DYSKINESIA; FEMALE; FOREFOOT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INVOLUNTARY MOVEMENT; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; BENSERAZIDE; BIOCOMPATIBLE MATERIALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG COMBINATIONS; DRUG SYNERGISM; DYSKINESIA, DRUG-INDUCED; FEMALE; LAMENESS, ANIMAL; LEVODOPA; MICROSPHERES; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 77955215847     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32833d40c8     Document Type: Article

References (21)

1. Sherer TB, Betarbet R, Greenamyre JT. Pathogenesis of Parkinson's disease. Curr Opin Investig Drugs 2001; 2:657-662.
2. Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of LID in hemiparkinsonian rats. Synapse 2009; 63:610-620.
3. Jaunarajs KL, Dupre KB, Steiniger A, Klioueva A, Moore A, Kelly C, Bishop C. Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. Neuroreport 2009; 20:1265-1269.
4. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007; 130:1819-1833.
5. Aubert I, Guigoni C, Ha?kansson K, Li Q, Dovero S, Barthe N, et al. Increased D1 dopamine receptor signalling in levodopa-induced dyskinesia. Ann Neurol 2005; 57:17-26.
6. Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur J Neurosci 2006; 23:2669-2676.
7. Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bé dard PJ, Di Paolo T. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord 2006; 21:9-17.
8. Yang J, Hu LF, Liu X, Zhou F, Ding JH, Hu G. Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Life Sci 2006; 78:1940-1944.
9. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002; 15:120-132.
10. Hemmings HC Jr, Greengard P, Tung HY, Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 1984; 310:503-505.
11. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 2007; 27:6995-7005.
12. Kim DS, Palmiter RD, Cummins A, Gerfen CR. Reversal of supersensitive striatal dopamine D1 receptor signaling and extracellular signal-regulated kinase activity in dopamine-deficient mice. Neuroscience 2006; 137:1381-1388.
13. Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005; 20:306-314. (Pubitemid 40613291)
14. St-Hilaire M, Bourhis E, Lé vesque D, Rouillard C. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice. Eur J Neurosci 2006; 24:795-805.
15. Calon F, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 2003; 14:404-416.
16. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci\USA 1997; 94:3363-3367.
17. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998; 10:2694-2706.
18. Darmopil S, Mart́?n AB, De Diego IR, Ares S, Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 2009; 66:603-613.
19. Muñoz A, Carlsson T, Tronci E, Kirik D, Björklund A, Carta M. Serotonin neuron-dependent and-independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol 2009; 219:298-307.
20. Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis 2006; 22:586-598.
21. Aubert I, Guigoni C, Li Q, Dovero S, Bioulac BH, Gross CE, et al. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry 2007; 61:836-844.